Lilly drug slows Alzheimer's progression by 35% in trial
Send a link to a friend
[May 03, 2023]
By Julie Steenhuysen and Deena Beasley
CHICAGO (Reuters) -An experimental Alzheimer's drug developed by Eli
Lilly and Co slowed cognitive decline by 35% in a closely watched
late-stage trial, the company said on Wednesday, raising hopes for a
second effective treatment for the brain-wasting disease.
The drug, donanemab, met all primary and secondary goals of the trial.
It slowed progression of Alzheimer's by 35% to 36% compared to a placebo
in 1,182 people diagnosed with early-stage disease based on scans
showing brain deposits of a protein called amyloid and intermediate
levels of a second protein known as tau, Lilly said.
The trial's other 552 patients had high levels of tau, suggesting they
would be less likely to respond to the treatment.
After combining both groups, donanemab was shown to slow progression of
Alzheimer's by 22% using a Lilly-developed scale to measure cognition
and activities of daily living, and by 29% based on a more commonly used
scale of dementia progression.
"These are the strongest phase 3 data for an Alzheimer's treatment to
date. This further underscores the inflection point we are at for the
Alzheimer's field," said Maria Carrillo, chief science officer for the
Alzheimer's Association.
![](http://archives.lincolndailynews.com/2023/May/03/images/ads/current/castlemanor_sda_FINANCIAL_2017.png)
Using the commonly used dementia scale, trial results published last
year showed that Eisai Co Ltd and Biogen Inc's Leqembi reduced the rate
of cognitive decline by 27% compared to a placebo in patients with early
Alzheimer's.
Eli Lilly's shares rose 8.3% to $437.55, while Biogen fell nearly 5% to
$293.99 in premarket trading.
In the donanemab treatment group, Lilly said brain swelling, a known
side effect of drugs of this type, occurred in 24% of the participants,
with 6.1% experiencing symptoms. Brain bleeding occurred in 31.4% of the
donanemab group and 13.6% of the placebo group.
In the Leqembi Phase 3 trial, the drug was associated with brain
swelling in nearly 13% of its study participants.
Lilly said the incidence of serious brain swelling in the donanemab
study was 1.6%, including two participants whose deaths were attributed
to the condition and a third who died after an incident of serious brain
swelling.
Dr. Eric Reiman, executive director of the Banner Alzheimer's Institute,
which is running an Alzheimer's prevention study of donanemab in
presymptomatic patients, said he was "very excited" about the findings.
"Clearly, one saw benefits here, but there is some risk that needs to be
considered."
[to top of second column]
|
![](../images/050323PIX/health75.jpg)
Eli Lilly logo is shown on one of the
company's offices in San Diego, California, U.S., September 17,
2020. REUTERS/Mike Blake
![](http://archives.lincolndailynews.com/2017/Jul/22/images/ads/current/rohlfs_lda_072017.png) The company said it plans to file
for traditional U.S. approval by the end of June and with regulators
from other countries shortly thereafter.
"There are risks in medicine, but I think when you look at these
results in the context of a fatal life-threatening disease, these
results are quite meaningful," said Lilly Neuroscience executive
Anne White in an interview with Reuters.
Study participants received a monthly intravenous infusion of
donanemab. When follow-up brain scans showed that amyloid had been
removed, the treatment was stopped and volunteers were moved to the
placebo-arm of the study. Half of the trial participants had no
evidence of amyloid plaques at 12 months, the company said.
It also said 47% of donanemab patients in the 18-month trial had no
disease progression at 12 months, compared with 29% of the placebo
group.
Lilly's drug is likely to become the third in its class on the
market following U.S. approval of two similar medicines developed by
partners Eisai and Biogen - Leqembi and Aduhelm, which failed to
gain traction with doctors or insurers after showing little evidence
that they slowed cognitive decline.
Both were approved under the FDA's accelerated review program, based
on their ability to remove amyloid plaques.
Leqembi is currently undergoing the FDA's standard reviewprocess,
which will weigh its impact on cognitive function, with a decision
due by July 6.
More than 6 million Americans are living with Alzheimer's,and the
number is projected to rise to nearly 13million by 2050, according
to the Alzheimer's Association.
(Reporting by Julie Steenhuysen in Chicago and Deena Beasley in Los
Angeles, additional reporting by Manas Mishra in Bengaluru; Editing
by Bill Berkrot and Shinjini Ganguli)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
![](http://archives.lincolndailynews.com/2023/May/03/images/ads/current/humanesociety_sda022411.png) |